Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells
Year: 2009
Type: article
Study design: Clinical Trial
Source: Nature Medicine
DOI: 10.1038/nm.1932
Authors: Ronald T Mitsuyasu, Thomas C Merigan, Andrew Carr, Jerome A Zack, Mark A Winters, Cassy Workman, Mark Bloch, Jacob Lalezari, Stephen Becker, Lorna Thornton, Bisher Akil, Homayoon Khanlou, Robert Finlayson, Robert McFarlane, Don E Smith, Roger Garsia, David Ma, Matthew Law, John M Murray, Christof von Kalle, Julie A Ely, Sharon M Patino, Alison E Knop, Philip Wong, Alison V Todd, Margaret Haughton, Caroline Fuery, Janet L Macpherson, Geoff P Symonds, Louise A Evans, Susan M Pond, David A Cooper
Institutions: University of California, Los Angeles, Stanford University, St Vincent's Hospital Sydney, Holdsworth House Medical Practice, Quest Clinical Research (United States), AIDS Healthcare Foundation, Albion Centre, Royal Prince Alfred Hospital, UNSW Sydney, Cincinnati Children's Hospital Medical Center, German Cancer Research Center, National Center for Tumor Diseases, Johnson & Johnson (Australia)
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2082371015